DailyIQ
Last updatedUpdating…

REGN·Regeneron Pharmaceuticals, Inc.

$767.18
+14.06 (+1.87%)
High
$770.20
Open
$758.16
Market Cap
77.34B
52W High
$859.34
Low
$755.21
P. Close
$767.18
P/E
17.87
52W Low
$564.00
Fwd P/E
12.17
DailyIQ Est.
$883.04
Inst. Ownership
43.7%
Short Interest
2.13%
Days to Cover
2.5
Div. Yield
0.49%
Next Ex-Div
~Nov 16
Technical Score (1D)
36
BEARISH
News Sentiment
80
BULLISH
On Oct 13, Regeneron reported 84‑week Phase III data for Pasatru in adult patients with fibrodysplasia ossificans progressiva. The trial showed that Pasatru prevented new heterotopic ossification lesions, whereas the placebo cohort experienced nine new lesions. This outcome demonstrates the drug’s efficacy and supports its continued development toward regulatory approval. The data were presented as evidence that Pasatru can reduce the progression of the rare disease. The company highlighted the significance of these findings for its pipeline and future regulatory strategy.
LOW TARGET
$730 -4.8%
2 analysts
MEAN TARGET
$860 +12.1%
20 analysts
HIGH TARGET
$1030 +34.3%
18 analysts
PRICE RANGE
$730.00 - $1030.00
SB / B / H / S / SS
8/18/12/1/1
DAILYIQ EST.
$883.04 (+15.1%)
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Country
United States
Symbol
REGN
Description
Regeneron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for a range of serious diseases. The company's core value proposition lies in its diverse portfolio of marketed products, including EYLEA for eye diseases and Dupixent for conditions like atopic dermatitis and asthma. Regeneron also offers treatments for various cancers, rheumatoid arthritis, and other rare diseases, demonstrating its commitment to addressing unmet medical needs. Through strategic collaborations, the company is actively pursuing advancements in gene editing and cell therapies, further solidifying its position in the competitive pharmaceutical landscape. Headquartered in Tarrytown, New York, Regeneron aims to improve patient outcomes through its comprehensive research and development efforts.
Bought (1Y)
0 shares
$0
Sold (1Y)
17,764 shares
$14.7M
McCourt MarionEVP Commercial
Sell1,131 shares2026-09-03
McCourt MarionEVP Commercial
Sell1,215 shares2026-09-02
Guarini Kathryn-
Option Exercise400 shares2026-09-02
Guarini Kathryn-
Sell400 shares2026-09-02
Guarini Kathryn-
Option Exercise400 shares2026-09-02
78/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
31.4%
Revenue CAGR
27.3%
Current Ratio
4.13x
Debt / Equity
0.06x
Return on Equity
14.4%
Earnings Summary
Regeneron Pharmaceuticals, a biopharmaceutical company headquartered in Tarrytown, New York, focuses on discovering, developing, and commercializing innovative medicines for serious diseases, with flagship products such as EYLEA and Dupixent, and a growing oncology and rare disease pipeline. Operating within the highly competitive biotechnology sector, Regeneron leverages strategic collaborations and advanced R&D to maintain its market position. In the most recent quarters, Regeneron reported Q4 2025 revenue of $3.8843 billion, slightly above the $3.8669 billion estimate, and EPS of $11.44 versus the $10.84 estimate, marking a modest revenue uptick and a strong earnings beat. Q1 2026 revenue rose to $3.6054 billion from $3.4837 billion in Q4 2025, while EPS increased to $9.47 from $11.44, reflecting a decline in earnings momentum despite revenue growth. The company’s Q2 2026 results were striking, with revenue of $4.2907 billion surpassing the $3.8917 billion estimate and EPS of $14.29 beating the $13.21 estimate, indicating a resurgent earnings performance. Historically, Regeneron has maintained a consistent revenue growth trajectory, with EPS often beating estimates in 3 of the last 4 quarters, though there have been occasional misses such as Q1 2025 where EPS fell short of the $8.48 estimate. The company’s earnings pattern shows revenue expansion even when EPS misses occur, underscoring a robust top‑line growth engine. Recent news highlights include the Oct 13 Phase III data for Pasatru in FOP, reinforcing the drug’s efficacy and supporting future regulatory prospects, and the Oct 8 clinical supply agreement with Biohaven to evaluate BHV‑11530 with cemiplimab, expanding Regeneron’s oncology portfolio.

EPS

EstBeatMiss
$7.30$9.78$12.25$14.73$17.21Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$16.07 - -
Q2'26$13.21$14.29+8.2%
Q1'26$8.90$9.47+6.4%
Q4'25$10.84$11.44+5.5%
Q3'25$9.64$11.83+22.7%
Q2'25$8.44$12.89+52.7%

Revenue

EstBeatMiss
$3.3B$3.7B$4.1B$4.4B$4.8BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$4.6B - -
Q2'26$3.9B$4.3B+10.3%
Q1'26$3.5B$3.6B+3.5%
Q4'25$3.9B$3.9B+0.4%
Q3'25 - $3.8B -
Q2'25 - $3.7B -

Market Data

REGN Stock Snapshot

NEUTRAL36/100
$767.18+$14.06 (1.9%)
Market cap
77.34B
P/E ratio
17.9
Day range
$755.21 – $770.20
News sentiment
80/100 · Bullish
Analyst target
$859.69 (+12.1%)
Consensus
Buy · 40 analysts
52-week range+36.0% off low · -10.7% from high
$564.00$859.34
Price $767.18 DailyIQ Est. $883.04

Momentum has flattened on REGN, leaving the next move dependent on news rather than the chart. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Reverse DCF

What growth is priced into REGN?

CHEAP

At today's price, Regeneron Pharmaceuticals, Inc. needs to grow free cash flow about 3.3% a year for the next 10 years to justify its valuation at a 8.81% cost of capital. Over its actual history it has compounded free cash flow at 24.6% a year, so the market is asking for 21.3 percentage points below its own delivered rate. On that basis REGN looks priced below what its own growth record supports.

Implied FCF growth
3.3%
Historical FCF CAGR
24.6%
Growth gap
-21.3 pts
Verdict
CHEAP
Discount rate (WACC)
8.81%
Beta
0.75

Behaviour On Record

What REGN's own history says about today's numbers

Realized volatility (21d)
26.0% 35th pct
Below its peak
-37.3%
vs 200-day average
+2.4%
Up days (1y)
49%

Regeneron Pharmaceuticals, Inc. is currently running 26.0% annualised volatility over the last 21 sessions. Measured against REGN's own 13 years of daily returns rather than a market-wide average, that is the 35th percentile — on the quiet side for this stock, against a typical reading of 28.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

REGN is trading -37.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -27.5%, and the deepest was -41.5% in 2024. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +2.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 43rd percentile — close to the gap it normally carries. Over the past year REGN closed higher on 49% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 13 years of records, REGN finished the month higher 6 of 13 times, with a median return of -1.0% and an average of -0.3%. Its strongest month historically has been July at +5.3% on average, its weakest April at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: REGN has opened more than 2% away from the prior close in 112 of 3,267 sessions (3.4% of the time), with the largest gaps running +24.3% and -12.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, REGN moved an average of 3.5% in the session after earnings, closing higher 3 of those 3 times, with a median move of +3.8% and a largest of +4.1%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against REGN's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of REGN's sector?

Regeneron Pharmaceuticals, Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, REGN ranks 7th of 15 tracked industries, improving.

Sector rank
#3 of 12
Sector state
Leading
Sector rotation score
91
Industry rank
#7 of 15

Options Market

What is the options market pricing for REGN?

CallsPuts

For Regeneron Pharmaceuticals, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.47), with at-the-money implied volatility around 40.9%. The options market is pricing roughly a ±3.1% move by that expiry — a range of about $743.29–$791.19.

Put/call ratio (2026-10-16)
0.47
ATM implied volatility
40.9%
Total open interest
2,570
Expected move by 2026-10-16
±3.1% ($743.29–$791.19)

Analyst Rating Changes

Are analysts turning bullish or bearish on REGN?

RBC Capital most recently reiterated its rating on Regeneron Pharmaceuticals, Inc. to Sector Perform on Oct 8, 2026 with a price target of $810 (from $737). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
RBC Capital — Sector Perform
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 8, 2026RBC CapitalMaintainedSector Perform$737 → $810
Oct 7, 2026Truist SecuritiesMaintainedBuy$772 → $780
Oct 7, 2026Morgan StanleyMaintainedEqual-Weight$758 → $779
Oct 6, 2026JP MorganMaintainedOverweight$900 → $950
Oct 1, 2026JefferiesMaintainedBuy$870 → $930
Oct 1, 2026Argus ResearchUpgradeHold → Buy$850
Sep 29, 2026RBC CapitalReiteratedSector Perform$737
Sep 10, 2026HSBCMaintainedBuy$800 → $920
Aug 17, 2026Leerink PartnersMaintainedMarket Perform$641 → $824
Aug 3, 2026CitigroupMaintainedNeutral$700 → $740
Aug 3, 2026GuggenheimMaintainedBuy$1000 → $1030
Jul 31, 2026RBC CapitalMaintainedSector Perform$696 → $737

Peers & ETF holders

REGN peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

80/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Regeneron reported 84‑week Phase III data for its drug Pasatru in adults with fibrodysplasia ossificans progressiva (FOP). The study showed a clinically meaningful reduction in disease progression and improved functional outcomes compared with placebo. These results support the drug’s potential to address an unmet medical need and could strengthen its regulatory and commercial prospects.
What did this article say?
Regeneron’s rare‑disease therapy Pasatru was granted FDA approval in August after a 56‑week study demonstrated a 90% reduction in new abnormal bone lesions. The trial’s safety profile was favorable, with no new abnormal bone growth observed. The approval marks a significant milestone for Regeneron’s rare‑disease portfolio and is expected to enhance the company’s market position.
What did this article say?
Regeneron announced that the extension phase of the OPTIMA trial for Pasatru demonstrated sustained therapeutic benefit in patients with a rare genetic disorder. The data, presented on October 12, showed continued improvement in key clinical endpoints over the additional study period. The company highlighted that the extended results reinforce the drug’s efficacy profile and support ongoing development plans. This positive outcome may strengthen regulatory discussions and investor confidence in Regeneron's pipeline.
What did this article say?
RBC lifted its price target for Regeneron Pharmaceuticals from $737 to $810, maintaining a sector perform rating. The upgrade reflects confidence in Regeneron's pipeline and market position. Analysts noted Regeneron's average rating of overweight and a mean target of $864.20, underscoring bullish sentiment. The move signals potential upside for investors and highlights RBC’s positive view of Regeneron’s growth prospects.
What did this article say?
RBC Capital analyst Brian Abrahams upgraded Regeneron Pharmaceuticals to a Sector Perform rating and increased the price target from $737 to $810. The upgrade reflects confidence in Regeneron’s pipeline and recent commercial performance. The new target suggests a bullish outlook for the company’s valuation. The rating change is expected to influence investor sentiment and could support a rise in the stock price.
What did this article say?
In September 2026, Biohaven Ltd. entered a clinical supply agreement with Regeneron Pharmaceuticals to evaluate BHV‑1530 in combination with cemiplimab (Libtayo) for solid‑tumor patients. The partnership builds on an existing supply deal for Biohaven’s TROP2‑directed ADC BHV‑1510, deepening Regeneron’s involvement across Biohaven’s oncology pipeline. The collaboration signals Regeneron’s willingness to support Biohaven’s investigational agents and may enhance the commercial prospects of both companies’ oncology programs.
What did this article say?
George Yancopoulos, Regeneron’s chief executive and scientific officer, outlined the company’s approach to research and development during an interview on October 7. He emphasized how Regeneron’s investment model differs from competitors, focusing on data-driven discovery and advanced omics technologies. Yancopoulos also discussed strategies for maintaining a competitive advantage over Chinese biopharmaceutical firms.
What did this article say?
Truist Securities analyst Gregory Renza maintained a Buy rating on Regeneron Pharmaceuticals and raised its price target from $772 to $780. The upgrade reflects confidence in Regeneron's pipeline and recent commercial performance. The move suggests that market participants expect continued growth in Regeneron's revenue streams. The firm’s assessment aligns with the company’s strategic initiatives and favorable market conditions. Overall, the rating and target increase indicate a positive outlook for Regeneron’s stock.
What did this article say?
Morgan Stanley increased its price target for Regeneron Pharmaceuticals (REGN) to $779 from $758, reflecting a more optimistic outlook. The brokerage maintains an overweight rating and cites an average target of $861.28 from other analysts. The adjustment signals confidence in Regeneron's growth prospects and potential earnings momentum. This move may influence investor sentiment and trading activity in the near term.
What did this article say?
Morgan Stanley analyst Matthew Harrison upgraded Regeneron Pharmaceuticals to an equal‑weight rating and increased the price target from $758 to $779. The move reflects confidence in Regeneron's pipeline and recent clinical progress. The upgrade signals a positive outlook for the company’s valuation and may influence investor sentiment.

Technical Analysis

Real-time indicators across multiple timeframes

36
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $28.53B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy9,075,1539.00%$7.00B2026-01-29
BlackRock, Inc.▲ Buy9,113,5069.04%$5.68B2026-08-07
Invesco Ltd.▲ Buy3,940,6653.91%$2.46B2026-08-14
JPMorgan Chase & Co▼ Sell3,774,1993.74%$2.38B2026-08-12
Geode Capital Management, LLC▲ Buy2,625,8102.60%$1.63B2026-08-12
Loomis Sayles & Co L P▼ Sell1,859,1721.84%$1.16B2026-08-14
Morgan Stanley▲ Buy1,397,7121.39%$871.53M2026-08-13
Bank of America Corp▲ Buy1,291,0531.28%$805.02M2026-08-14
Wellington Management Group LLP▼ Sell1,270,0871.26%$791.95M2026-08-14
Norges Bank▼ Sell1,172,8081.16%$731.29M2026-08-12
Goldman Sachs Group Inc▼ Sell1,163,1911.15%$725.30M2026-08-14
AQR Capital Management LLC▼ Sell1,126,0801.12%$702.16M2026-08-14
Northern Trust Corp▼ Sell916,4670.91%$571.45M2026-08-13
FMR LLC (Fidelity)▼ Sell831,9640.83%$518.76M2026-08-13
Capital World Investors▼ Sell814,9250.81%$508.14M2026-08-12
Two Sigma Investments, LP▼ Sell656,1240.65%$409.12M2026-08-14
Man Group plc▲ Buy436,9560.43%$272.46M2026-08-14
Neuberger Berman Group LLC▼ Sell421,9760.42%$263.12M2026-08-13
AllianceBernstein L.P.▼ Sell292,3380.29%$225.87M2026-08-14
Citigroup Inc▲ Buy346,6370.34%$216.14M2026-08-03
Janus Henderson Group plc▲ Buy209,2480.21%$161.64M2026-05-18
Squarepoint Ops LLC▲ Buy198,5670.20%$123.81M2026-08-14
Susquehanna International Group, LLP▲ Buy180,2190.18%$112.37M2026-08-14
Millennium Management LLC▲ Buy165,1200.16%$102.96M2026-08-14
Renaissance Technologies LLC▲ Buy148,2220.15%$92.42M2026-08-13
Q2 2026 flow:2.78M sh bought ($1.73B)3.15M sh sold ($1.99B)net -374.1K sh (−$257.83M)
Congressional Trading Activity
22 disclosed trades · ~$225.0K est. traded value · 10 buys, 12 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-05-152026-06-08
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Julia LetlowHouseLA05▲ Buy$1K - $15K2026-02-122026-03-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-06-09
Byron DonaldsHouseFL19▼ Sell$1K - $15K2025-04-102025-05-24
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-072025-05-08
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-012025-05-14
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-02-252025-03-27
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-02-122025-03-12
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-01-242025-02-10
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-01-152025-02-12
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-04-042024-05-15
Tommy TubervilleSenateAL▲ Buy$1K - $15K2023-04-032023-05-12
Tommy TubervilleSenateAL▼ Sell$1K - $15K2022-03-302022-04-08
Tommy TubervilleSenateAL▲ Buy$1K - $15K2021-03-292021-07-23
Sheldon WhitehouseSenateRI▼ Sell$15K - $50K2017-12-182018-01-10
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2017-05-162017-06-08
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2016-09-062016-10-07
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2016-05-242016-06-16
Susan M. CollinsSenateME▼ Sell$1K - $15K2014-01-302014-02-05